This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Although the objective of our study was not to evaluate the intracoronary use of Gp IIb/IIIa inhibitors but to test the time factor of these drugs used with the same dose regimen and the same IV route of administration, Dr Horton raises an interesting question that is of significant importance to the interventional cardiologist. Case reports and case series have shown that the intracoronary use of Gp IIb/IIIa inhibitors (mainly abciximab) is feasible and certainly effective. However, it is important to acknowledge the serious limitations of these evaluations: (1) small numbers of patients compared with the larger population we reported; (2) different dose regimens used in these studies; (3) different techniques of administration either upstream of the thrombus (in the guiding catheter) or downstream after crossing the lesion; and (4) no randomized evaluation of the clinical impact of intracoronary vs IV administration.

For intracoronary use to be more . . . [Full Text of this Article]

Gilles Montalescot, MD, PhD
gilles.montalescot@psl.ap-hop-paris.fr

Maria Borentain, MD; Laurent Payot, MD; Jean Phillipe Collet, MD, PhD; Daniel Thomas, MD
Institut de Cardiologie
Centre Hospitalier Universitaire Pitié-Salpêtrière
Paris, France

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Glycoprotein IIb/IIIa Inhibition
Heather Horton
JAMA. 2004;292(18):2211.
EXTRACT | FULL TEXT  

Glycoprotein IIb/IIIa Inhibition
Joel Klein
JAMA. 2004;292(18):2211.
EXTRACT | FULL TEXT  

Early vs Late Administration of Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis
Gilles Montalescot, Maria Borentain, Laurent Payot, Jean Philippe Collet, and Daniel Thomas
JAMA. 2004;292(3):362-366.
ABSTRACT | FULL TEXT